experspadmin

Mutations That Drive Progression and Are Not Inhibited by Currently Available Treatments
Oncology

Mutations That Drive Progression and Are Not Inhibited by Currently Available Treatments

expert roundtables
By Arun Singh, MD; Jonathan C. Trent, MD, PhD; Michael C. Heinrich, MD
Patients on Second- or Third-line Gastrointestinal Stromal Tumors Therapy: Adverse Effects and Management
Oncology

Patients on Second- or Third-line Gastrointestinal Stromal Tumors Therapy: Adverse Effects and Management

patient care perspectives
By Michael C. Heinrich, MD
Predicting Gastrointestinal Stromal Tumor Growth and Spread Post Surgery
Oncology

Predicting Gastrointestinal Stromal Tumor Growth and Spread Post Surgery

patient care perspectives
By Michael C. Heinrich, MD
Resistance-Conferring Mutations With First-Generation Tyrosine Kinase Inhibitors
Oncology

Resistance-Conferring Mutations With First-Generation Tyrosine Kinase Inhibitors

clinical topic updates
By Jonathan C. Trent, MD, PhD
New Directions for Gastrointestinal Stromal Tumor Clinical Research
Oncology

New Directions for Gastrointestinal Stromal Tumor Clinical Research

clinical topic updates
By Arun Singh, MD
Load More